Canaccord raised the firm’s price target on Taysha Gene Therapies (TSHA) to $11 from $9 and keeps a Buy rating on the shares. The firm noted the company shared both a regulatory and a clinical update (longer term low-dose follow-up data and first look at high-dose data) for its TSHA-102 program for Rett Syndrome. Canaccord updated its model for the updates, namely increasing their assigned POS on TSHA-102 to 75% from 50% previously and the roughly $200M offering via a mix of shares and prefunded warrants.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Needham healthcare analyst holds analyst/industry conference call
- Taysha Gene Therapies price target raised to $8 from $6 at Needham
- Positive Outlook for Taysha Gene Therapies: Buy Rating on Promising TSHA-102 Advancements
- Positive Outlook for Taysha Gene Therapies: Strong Study Design and Promising Data Support Buy Rating
- Taysha Gene Therapies Announces Major Stock Offering